TP53 and Alzheimer disease: By exploring the mechanism of non‐genomic VDR activation, we were able to demonstrate that the genomic VDR–RXR signaling pathway to be compromised by Aβ in AD, leaving the VDR/p53 complex to form in the cytosol and cause damage to AD brains.